AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 64 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2020. The put-call ratio across all filers is 0.10 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $13,816,000 | +95.8% | 1,829,886 | +7.9% | 0.13% | +94.1% |
| Q3 2019 | $7,057,000 | +60.2% | 1,696,290 | +11.3% | 0.07% | +61.9% |
| Q2 2019 | $4,406,000 | +118.6% | 1,524,428 | +8.9% | 0.04% | +110.0% |
| Q1 2019 | $2,016,000 | -28.7% | 1,400,007 | +27.8% | 0.02% | -41.2% |
| Q4 2018 | $2,827,000 | -36.3% | 1,095,877 | +8.5% | 0.03% | -15.0% |
| Q3 2018 | $4,435,000 | -24.5% | 1,010,177 | +5.4% | 0.04% | -33.3% |
| Q2 2018 | $5,878,000 | -11.7% | 958,862 | +5.1% | 0.06% | -21.1% |
| Q1 2018 | $6,654,000 | -8.3% | 912,698 | +3.1% | 0.08% | -13.6% |
| Q4 2017 | $7,257,000 | -21.2% | 885,046 | +0.9% | 0.09% | -21.4% |
| Q3 2017 | $9,208,000 | -4.2% | 876,955 | +0.6% | 0.11% | -5.1% |
| Q2 2017 | $9,612,000 | +3.0% | 871,467 | -9.6% | 0.12% | -4.8% |
| Q1 2017 | $9,331,000 | – | 963,981 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |